TY - JOUR
AU - M. N. Mian
AU - J. Annam
AU - A. Altschuler
AU - M. B. Does
AU - S. A. Sterling
AU - D. D. Satre
AU - C. I. Campbell
AU - A. H. Asyyed
AU - L. D. Silver
AU - S. F. Cunningham
AU - K. C. Young-Wolff
A1 - 
AB - INTRODUCTION: Cannabis use among adolescents is prevalent, and clinicians who work with adolescents have unique insights about how to treat cannabis use in this population. METHODS: This qualitative study interviewed 32 clinicians from addiction medicine recovery services (AMRS), the emergency department (ED), mental health (MH), and pediatrics in an integrated healthcare system to understand their perspectives and experiences regarding barriers and facilitators to treating adolescent cannabis use. The analysis was developed using thematic analysis of interviews. RESULTS: Thirty-two clinicians (Mean age = 45.9, SD =7.6; 56.3 % Female; 56.3 % White) were recruited from AMRS (n = 13; 41.6 %), the ED (n = 7; 21.9 %), MH (n = 7; 21.9 %) and pediatrics (n = 5; 15.6 %). Clinicians discussed several key barriers and facilitators of treating adolescent cannabis use. Facilitators include the use of multiple screening tools for adolescent cannabis use (i.e., self-report and toxicology testing) which provide more comprehensive information; patient-centered treatment approaches; and discussing cannabis use in the context of adolescents' mental health. Barriers discussed included adolescents' and parents' minimization of adolescent cannabis use risks. Several factors were discussed as potential facilitators or barriers, depending on context, including the influence of peers, virtual treatment, and parental involvement or lack thereof in treatment. CONCLUSIONS: Interviews with clinicians who work with adolescents across settings highlighted factors that serve as barriers and facilitators to treating adolescent cannabis use. These findings have important implications for guiding future research and intervention efforts, including the inclusion of universal screening practices, addressing stigma, reducing adolescents' and parents' minimization of cannabis use-related harms, and improving adolescent and parent engagement in treatment.
AD - Department of Psychology, Suffolk University, Boston, MA, United States of America; Division of Research, Kaiser Permanente Northern California, Pleasanton, CA, United States of America; Department of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, University of California, San Francisco, CA, United States of America. Electronic address: Maha.mian@suffolk.edu.; Department of Psychiatry, Kaiser Permanente Oakland Medical Center, Oakland, CA, United States of America.; Division of Research, Kaiser Permanente Northern California, Pleasanton, CA, United States of America.; Division of Research, Kaiser Permanente Northern California, Pleasanton, CA, United States of America; Department of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, University of California, San Francisco, CA, United States of America.; Regional Offices, Kaiser Permanente Northern California, Oakland, CA, United States of America.; Public Health Institute, Oakland, California, United States of America.
AN - 39522766
BT - J Subst Use Addict Treat
C5 - Healthcare Disparities; Opioids & Substance Use
DA - Feb
DO - 10.1016/j.josat.2024.209559
DP - NLM
ET - 20241108
JF - J Subst Use Addict Treat
LA - eng
N2 - INTRODUCTION: Cannabis use among adolescents is prevalent, and clinicians who work with adolescents have unique insights about how to treat cannabis use in this population. METHODS: This qualitative study interviewed 32 clinicians from addiction medicine recovery services (AMRS), the emergency department (ED), mental health (MH), and pediatrics in an integrated healthcare system to understand their perspectives and experiences regarding barriers and facilitators to treating adolescent cannabis use. The analysis was developed using thematic analysis of interviews. RESULTS: Thirty-two clinicians (Mean age = 45.9, SD =7.6; 56.3 % Female; 56.3 % White) were recruited from AMRS (n = 13; 41.6 %), the ED (n = 7; 21.9 %), MH (n = 7; 21.9 %) and pediatrics (n = 5; 15.6 %). Clinicians discussed several key barriers and facilitators of treating adolescent cannabis use. Facilitators include the use of multiple screening tools for adolescent cannabis use (i.e., self-report and toxicology testing) which provide more comprehensive information; patient-centered treatment approaches; and discussing cannabis use in the context of adolescents' mental health. Barriers discussed included adolescents' and parents' minimization of adolescent cannabis use risks. Several factors were discussed as potential facilitators or barriers, depending on context, including the influence of peers, virtual treatment, and parental involvement or lack thereof in treatment. CONCLUSIONS: Interviews with clinicians who work with adolescents across settings highlighted factors that serve as barriers and facilitators to treating adolescent cannabis use. These findings have important implications for guiding future research and intervention efforts, including the inclusion of universal screening practices, addressing stigma, reducing adolescents' and parents' minimization of cannabis use-related harms, and improving adolescent and parent engagement in treatment.
PY - 2025
SN - 2949-8767 (Print); 2949-8759
SP - 209559
ST - Clinician perspectives on barriers and facilitators to the treatment of adolescent cannabis use: A qualitative study
T1 - Clinician perspectives on barriers and facilitators to the treatment of adolescent cannabis use: A qualitative study
T2 - J Subst Use Addict Treat
TI - Clinician perspectives on barriers and facilitators to the treatment of adolescent cannabis use: A qualitative study
U1 - Healthcare Disparities; Opioids & Substance Use
U3 - 10.1016/j.josat.2024.209559
VL - 169
VO - 2949-8767 (Print); 2949-8759
Y1 - 2025
ER -